Binding of human papillomavirus type 16 to heparan sulfate is inhibited by mucosal antibodies from patients with low-grade squamous intraepithelial lesions but not from cervical cancer patients
Open Access
- 1 November 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in FEMS Immunology & Medical Microbiology
- Vol. 54 (2) , 167-176
- https://doi.org/10.1111/j.1574-695x.2008.00484.x
Abstract
Mucosal antibodies against human papillomavirus type 16 (HPV16) capsids have been detected in infected women. To determine whether these antibodies recognize and block the receptor site mediating attachment of HPV16 to heparan sulfate, mucus samples from 126 HPV16-associated low-grade squamous intraepithelial lesion (LSIL) and 85 cervical cancer patients, previously found to react to HPV16 virus-like particles (VLP), and 101 normal controls were tested in an inhibition assay, using HPV16 VLP and heparan sulfate proteoglycan-coated plates. Inhibition levels of 9.3–67.2% were mediated by type-specific antibodies in 94.4% of LSIL patients. Cervical cancer cases showed significantly lower levels of inhibition than LSIL samples (PPP<0.005). These results indicate that mucosal antibodies inhibiting binding of VLP to heparan sulfate are developed in most LSIL patients, but are hardly present in cervical cancer patients.Keywords
This publication has 43 references indexed in Scilit:
- Inhibition of Transfer to Secondary Receptors by Heparan Sulfate-Binding Drug or Antibody Induces Noninfectious Uptake of Human PapillomavirusJournal of Virology, 2007
- Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particlesVirology, 2007
- Keratinocyte-Secreted Laminin 5 Can Function as a Transient Receptor for Human Papillomaviruses by Binding Virions and Transferring Them to Adjacent CellsJournal of Virology, 2006
- Correlates of cervical mucosal antibodies to human papillomavirus 16: Results from a case control studyGynecologic Oncology, 2005
- Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesionsJournal of General Virology, 2004
- Evidence for the Presence of Neutralizing Antibodies Against Human Papillomavirus Type 6 in Infants Born to Mothers with Condyloma AcuminataAmerican Journal of Perinatology, 2003
- Detection of Neutralizing Antibodies against Human Papillomaviruses (HPV) by Inhibition of Gene Transfer Mediated by HPV PseudovirionsJournal of Clinical Microbiology, 2002
- α6 Integrin Is the Main Receptor of Human Papillomavirus Type 16 VLPBiochemical and Biophysical Research Communications, 2001
- Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 Å resolutionJournal of Molecular Biology, 1998
- INTERACTION OF ANTIGENS AND ANTIBODIES AT MUCOSAL SURFACESAnnual Review of Microbiology, 1997